Lilly to offer highest doses of weight-loss drug Zepbound on website

Eli Lilly will offer the highest doses (12.5mg and 15mg) of its weight-loss drug Zepbound directly to cash-paying customers via its website starting in early August, with prescriptions for these doses available from July 7, for $499 per month or less. This move expands access to Zepbound and aims to compete with compounded versions and maintain market share against Novo Nordisk's Wegovy in the competitive obesity drug market, estimated to be worth $150 billion; Lilly has recently overtaken Novo in prescription data despite Novo's first-mover advantage.

Analysis

Eli Lilly is strategically expanding patient access to its Zepbound weight-loss drug by making the two highest doses, 12.5 mg and 15 mg, available directly to cash-paying customers via its LillyDirect website from early August at $499 per month or less; prescriptions for these higher doses can begin on July 7. This expansion ensures all approved Zepbound doses are accessible through this direct-to-consumer channel, a move designed to bolster market share against Novo Nordisk's Wegovy and mitigate competition from compounded alternatives, particularly after the U.S. Food and Drug Administration banned sales of compounded copies. Despite Novo Nordisk's initial first-mover advantage in the lucrative, estimated $150 billion obesity drug market, recent prescription data indicates Eli Lilly has now overtaken its rival. However, the competitive environment remains intense and fluid, as underscored by CVS Health's decision to remove Zepbound from some of its reimbursement formularies effective July 1, citing more favorable pricing secured for Novo Nordisk's Wegovy. Lilly's initiative to offer all doses directly at a transparent cash price aims to broaden patient access, potentially bypassing such insurance formulary restrictions for a segment of users, and directly challenges both Novo Nordisk and the residual compounded market, solidifying its aggressive strategy to lead this high-growth sector.

Key Decisions for Investors

• Investors should assess Eli Lilly's direct-to-consumer strategy for Zepbound as a proactive measure to drive volume and secure market leadership in the highly competitive obesity drug sector, potentially offsetting formulary challenges such as the recent CVS Health decision.
• Closely monitor ongoing competitive dynamics with Novo Nordisk, particularly concerning pricing strategies, payer negotiations, and patient uptake of directly purchased versus reimbursed drugs, as these factors will be critical determinants of market share and profitability for both Eli Lilly and Novo Nordisk.
• Evaluate the potential size and profitability of the cash-pay segment for Zepbound, as Eli Lilly's direct pricing strategy specifically targets this demographic, which could sustain Zepbound's growth trajectory even amidst evolving and sometimes restrictive insurance coverage landscapes.